The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research to understand, treat, and prevent infectious and allergic diseases.

May 15, 2023 · A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health, has begun enrolling volunteers at Duke University in Durham, North Carolina.

2 days ago · This colorized electron microscope image provided by the National Institute of Allergy and Infectious Diseases in 2024 shows mpox virus particles, green, found within infected cultured cells, blue.

The National Institute of Allergy and Infectious Diseases (NIAID) provides health information on allergic, infectious, and immunologic diseases. Diseases include food allergy, sinusitis, and genital herpes.

The National Institute of Allergy and Infectious Diseases (NIAID, / ˈ n aɪ. æ d /) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS).

Jan 2, 2020 · Primary contract awardees for the CIVICS Vaccine Centers, Vaccine Manufacturing & Toxicology Core, Clinical Core, and Statistical, Data Management, and Coordination Center.

May 20, 2022 · The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the UNC Gillings School of Global Public Health a $65 million grant establishing an Antiviral Drug Discovery (AViDD) Center to develop oral antivirals that can combat pandemic-level viruses like COVID-19.

Dec 19, 2023 · The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.

May 18, 2022 · The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

Nov 28, 2019 · To this end, NIAID organized a workshop to consider the current status of Ct vaccine research and address critical questions in Ct vaccine design and clinical testing.